Vigonvita Life Sciences Co., Ltd. (China)

Vigonvita Life Sciences Co., Ltd. (China), also known as 苏州旺山旺水生物医药股份有限公司 (旺山旺水), was founded in 2013 and listed on the Main Board of the Hong Kong Stock Exchange in November 2025 with stock code 2630.HK. The company is an innovative-driven biopharmaceutical enterprise dedicated to new drug development in viral infections, neuropsychiatric, and reproductive health. It has built a full-chain new drug creation engineering system covering lead discovery, preclinical and clinical research, and industrialization and commercialization of APIs and formulations. The company has a competitive and diversified innovative drug pipeline, with two innovative drugs in commercial stage, five candidate new drugs in clinical trials, and two candidate compounds in preclinical research. VV116, an oral nucleoside RNA-dependent RNA polymerase inhibitor with broad-spectrum antiviral potential, has been approved for COVID-19 in China (brand: 民得维®) and Uzbekistan (brand: Mindvy®). TPN171, a highly active and selective PDE5 inhibitor, has been approved for erectile dysfunction in China (brand: 昂伟达®) and Uzbekistan (brand: Onvita®). The company's subsidiary, 旺山旺水（连云港）制药有限公司, has API and formulation production systems meeting domestic and international GMP and EHS requirements.

Vigonvita Life Sciences Co., Ltd. (China), also known as 苏州旺山旺水生物医药股份有限公司 (旺山旺水), was founded in 2013. In 2020, during the COVID-19 outbreak, the company collaborated with multiple research institutions and enterprises, including the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, to discover the anti-COVID-19 candidate drug VV116. In 2021, VV116 tablets were approved in Uzbekistan for COVID-19 under the brand name Mindvy®. In 2022, the company established 旺山旺水（上海）生物医药有限公司 in Zhangjiang, Shanghai, and TPN171 tablets were approved in Uzbekistan for erectile dysfunction under the brand name Onvita®. In 2023, VV116 tablets were conditionally approved in China for COVID-19 under the brand name 民得维®, and the Lianyungang factory obtained the Drug Production License. In 2024, the IND application for VV261 for severe fever with thrombocytopenia syndrome was approved. In 2025, 民得维® was converted from conditional approval to regular approval in China, becoming the first orally administered nucleoside anti-COVID-19 drug without genetic toxicity risk to receive regular approval; TPN171 tablets were approved in China for erectile dysfunction under the brand name 昂伟达®; and the company was listed on the Main Board of the Hong Kong Stock Exchange with stock code 2630.HK.

1. 苏州旺山旺水生物医药股份有限公司 _感染性疾病治疗_神经精神系统
2. 喜讯：旺山旺水荣膺财联社2025年“最具投资价值奖”
3. Vigonvita Life Sciences Co., Ltd. (China)